Funds › Sanofi
Sanofi
13F for Q3 2026, filed Nov 5, 2026. 16 positions worth $629.9M.Managers with more than $100 million in US-listed stocks list their holdings each quarter, within 45 days of quarter end. Long positions only: no short sales or cash.
Ask your AI about this
Connect Claude, ChatGPT, Gemini or Grok (Microsoft 365 Copilot coming soon) to 13F.ai and ask in plain English. Copy a question to get started:
Using 13F.ai, what are the biggest new, added, trimmed and exited positions of Sanofi in the latest 13F quarter?
Using 13F.ai, how has Sanofi's portfolio concentration changed over the last four quarters?
Using 13F.ai, which of Sanofi's top holdings have also been bought by insiders recently?
Connect your AI · Plans and the 7-day free trial (card required)
Holdings, Q3 2026
Largest first. Common shares only.
| # | The fund's own figures at the end of the quarter. A report can be up to 45 days old when it is filed. Options and bonds are not counted here. | Filing | ||||
|---|---|---|---|---|---|---|
| 1 | MGTX MeiraGTx Holdings plc | 12.20M | $134.2M | 21.3% | Unchanged | 13F ↗ |
| 2 | INBX Inhibrx Biosciences, Inc. | 1.16M | $115.9M | 18.4% | Unchanged | 13F ↗ |
| 3 | NVAX Novavax, Inc. | 6.88M | $74.4M | 11.8% | Unchanged | 13F ↗ |
| 4 | KRSA Korsana Biosciences, Inc. | 1.99M | $63.8M | 10.1% | New | 13F ↗ |
| 5 | ODTX Odyssey Therapeutics, Inc. | 1.99M | $44.2M | 7.0% | -0.1% | 13F ↗ |
| 6 | ANAB AnaptysBio, Inc. | 821,917 | $41.3M | 6.6% | Unchanged | 13F ↗ |
| 7 | AGMB AgomAb Therapeutics NV · ADR | 2.78M | $30.9M | 4.9% | Unchanged | 13F ↗ |
| 8 | TRAX First Tracks Biotherapeutics, Inc. · Ord Shs *A* | 821,917 | $29.1M | 4.6% | Unchanged | 13F ↗ |
| 9 | ETRA Electra Therapeutics, Inc. | 2.46M | $27.7M | 4.4% | New | 13F ↗ |
| 10 | ATTO Attovia Therapeutics, Inc. | 1.08M | $18.6M | 2.9% | New | 13F ↗ |
| 11 | LTGO Latigo Biotherapeutics, Inc. · Inc Com | 672,778 | $11.2M | 1.8% | New | 13F ↗ |
| 12 | IMRX Immuneering Corporation | 2.71M | $11.1M | 1.8% | Unchanged | 13F ↗ |
| 13 | MPLT MapLight Therapeutics, Inc. | 912,041 | $9.3M | 1.5% | Unchanged | 13F ↗ |
| 14 | SCTX Scribe Therapeutics Inc. | 500,000 | $9.2M | 1.5% | New | 13F ↗ |
| 15 | SABS SAB Biotherapeutics, Inc. | 2.20M | $7.0M | 1.1% | New | 13F ↗ |
| 16 | QTTB Q32 Bio Inc. | 244,083 | $2.0M | 0.3% | Unchanged | 13F ↗ |
Changes since Q2 2026
6 new, 0 added to, 1 trimmed, 0 exited, 9 unchanged. By estimated dollars.
New positions (6)
Added to (0)
None this quarter.
Trimmed (1)
| Position | Shares | Change | Est. dollars |
|---|---|---|---|
| ODTX Odyssey Therapeutics, Inc. | 1.99M | -0.1% | -$38.2K |
Exited (0)
None this quarter.
The 10 largest of each, by estimated dollars: shares changed times the later report's price. Index tracking, splits and mergers move positions too.
Compare two quarters
Pick any two quarters: what is new, added to, trimmed or exited. Premium plan.
Reported value by quarter
Value and number of positions at the end of each quarter.
Loading…
Largest positions in earlier quarters
Pick a quarter to see what the fund's biggest positions were then.
Loading…
Ten largest positions
By value, Q3 2026.
Filings
| Filing | ||||||
|---|---|---|---|---|---|---|
| Q3 2026 | Nov 5, 2026 | 13F-HR | 16 | $629.9M | Current | SEC ↗ |
| Q2 2026 | Jul 28, 2026 | 13F-HR | 10 | $534.0M | Current | SEC ↗ |
| Q1 2026 | May 7, 2026 | 13F-HR | 9 | $336.0M | Current | SEC ↗ |
| Q4 2025 | Feb 11, 2026 | 13F-HR | 8 | $310.4M | Current | SEC ↗ |
| Q3 2025 | Nov 4, 2025 | 13F-HR | 9 | $260.4M | Current | SEC ↗ |
| Q2 2025 | Jul 29, 2025 | 13F-HR | 10 | $175.7M | Current | SEC ↗ |
| Q1 2025 | May 6, 2025 | 13F-HR | 9 | $165.9M | Current | SEC ↗ |
Most recent first, up to 80. An amendment can replace a report or add holdings to it. All 13F filings
Information, not investment advice. Values are the fund's own figures at quarter end; a report can be up to 45 days old when filed. Disclaimer